Jan Marini returns to eyelash enhancement

Jan Marini Skin Research will release a third eyelash enhancement product after its previous offerings were beset by regulatory issues and patent disputes.

The California-based skin care company will be releasing its new eyelash enhancement product called Marini Lash next week, according to press reports.

CEO Jan Marini cited continued customer demand as a driver behind the new release saying that although previous products had been removed from the market demand was still ever present.

"There was never an ebb in interest. We were still inundated with inquiries on our web site" she said, as quoted by the Wall Street Journal.

Marini Lash is described as a 'non prostaglandin' peptide blend which CEO Jan Marini said is 'an entirely new technology that yields phenomenal results'.

'Non prostaglandin' is a reference to the regulatory and patent issues previous Marini eyelash products have run into.

The company's original product contained bimatoprost (a prostaglandin) - an FDA-approved drug for glaucoma treatment - and the regulatory body objected calling the eyelash product an unapproved and misbranded drug.

The original product was removed from the market in 2006 and JMSR then released a new reformulated product that according to the company did not contain the contentious ingredient.

However in January this year the company again removed the product from the market due to an alleged patent infringement with pharmaceutical company Allergan who markets bimatoprost under the name Lumigan in the US and Canada.

Although she contested the alleged patent infringement Jan Marini said back in January: "We believe that it makes sense to suspend these products while we strategically review our option."

Marini added that the company would concentrate on its skin care sector with a number of new product launches planned for 2008.

Recent skin care releases have included a brightening anti-aging product and a formulation targeting adult acne, launched in May and March 2008 respectively.

This content is copyright protected

However, if you would like to share the information in this article, you may use the headline, summary and link below: